Inflammation 2005 - Seventh World Congress. Highlights II.
Enefer
Sam
S
Thomson Scientific, London, UK. sam.enefer@thomson.com
D051722:ADAM Proteins / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D000072198:ADAM17 Protein; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D015507:Drugs, Investigational / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000209:etiology; D020382:Interleukin-18 / Q000235:genetics / Q000627:therapeutic use; D008263:Macrophage Migration-Inhibitory Factors / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D051379:Mice; D011994:Recombinant Proteins / Q000235:genetics; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000627:therapeutic use
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D020382:Interleukin-18; D008263:Macrophage Migration-Inhibitory Factors; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D051722:ADAM Proteins; D000072198:ADAM17 Protein